Table 5. Baseline Characteristics for SWOG Patients: SCNP-Evaluable vs. SCNP-Nonevaluable.
| Patient/Disease Characteristics (SWOG) | Subgroups | SCNP-Evaluable (n = 213) | SCNP-Nonevaluable (n = 53) | P | Total (n = 266) |
|---|---|---|---|---|---|
| Response to induction therapy | RD | 39 | 7 | 0.64 | 46 |
| CR/CRi without CCR1 | 67 | 18 | 85 | ||
| CCR1 | 39 | 13 | 52 | ||
| Fatal Induction Toxicity or Early Death | 68 | 15 | 83 | ||
| Age (Years) | (Min, Max), Median | (57, 88), 68 | (56, 81), 70 | 0.71 | (56, 88), 68 |
| Cytogenetic risk group | Better | 16 | 1 | 0.31 | 17 |
| Intermediate | 121 | 30 | 151 | ||
| Poor | 34 | 7 | 41 | ||
| Unknown | 42 | 15 | 57 | ||
| Sex | F | 94 | 23 | 1.00 | 117 |
| M | 119 | 30 | 149 | ||
| AML onset | De Novo | 162 | 45 | 0.20 | 207 |
| Secondary | 51 | 8 | 59 | ||
| Unknown | 0 | 0 | 0 | ||
| WBC (10 9 /L) | (Min, Max), Median | (0.7, 298.0), 22.0 | (0.8, 243.0), 41.1 | 0.09 | (0.7, 298.0), 24.9 |
| Overall Survival (days) | (Min, Max), Median | (1, 4866), 217 | (1, 3799), 246 | 0.39 | (1, 4866), 225 |